Clinical trials: Carcinomas
Lung Cancer Metastatic
Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC
This study is conducted to explore the safety and efficacy of anlotinib, a tyrosine kinase inhibitors of vascular endothelial growth factor receptor 2（VEGFR）、FGFR（fibroblast growth factor receptor）, platelet-derived growth factor…
- Trial name
- NCT03706287
- Testing
- anlotinib 8mg + AP/PC, anlotinib 10mg + AP/PC, anlotinib 12mg + AP/PC
- Where
- 6 sites in China
- Volunteers
- 62 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Advanced Hepatocellular Carcinoma (HCC)
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
This is a randomized, placebo-controlled, double-blind phase 2 study of OSI-906 or placebo at a continuous 150 mg twice daily (BID) dose.
- Trial name
- NCT01101906
- Testing
- OSI-906
- Where
- 41 sites in United States, Belgium and 8 more
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Inc
Carcinoma, Hepatocellular
Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma
A preliminary study has shown that the hormone-similar, growth-retarding drug octreotide can prolong survival time in patients with primary liver cancer.
- Trial name
- NCT00386984
- Testing
- Somatostatin (octreotide)
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- University Hospital Freiburg
Head and Neck Cancer
Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
The goal of this clinical research study is to find the highest safe dose of the drugs OSI-774 and docetaxel that can be given together along with radiation treatment for advanced head and neck cancer.
- Trial name
- NCT00113347
- Testing
- Erlotinib, Docetaxel, Radiation Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Extensive-Stage Small Cell Lung Cancer
Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy
This phase II trial studies how well IBI308 combined with paclitaxel/albumin-bound paclitaxel work in treating participants with small cell lung cancer after failing to platinum-etoposide chemotherapy.
- Trial name
- NCT04056949
- Testing
- Paclitaxel/Albumin-Bound Paclitaxel, IBI308
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Junling Li
Tumor Disease Including Colorectal Cancer, Head & Neck Squamous Cell Carcinoma
Assessment and Prediction of Cetuximab-Induced Hypersensitivity Reactions Using Cetuximab Specific IgE Detection
1. Background Cetuximab (trade name Erbitux) is a murine-human chimeric monoclonal antibody to human epidermal growth factor receptor (EGFR). This drug has been used as a treatment for colorectal cancer and head and neck cancer.
- Trial name
- NCT03485638
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Yonsei University
Hepatocellular Carcinoma
Risk Factors of Hepatocellular Carcinomas Developed on Non-fibrotic Liver: Case-control Study (NoFlic Study)
The main objective of this study is to identify direct carcinogenic factors in the absence of cirrhosis, and the carcinogenesis pathways involved on nonfibrotic liver (NfCHC).
- Trial name
- NoFlic (NCT03852238)
- Testing
- Blood test and self-administrated questionnaires
- Where
- 14 sites in France
- Volunteers
- 283 people
- Sponsor
- University Hospital, Bordeaux
Head and Neck Squamous Cell Carcinoma, Quality of Life
Enteral Omega 3 During Radiotherapy to Improve the Quality of Life and Functionality of Head and Neck Cancer Patients
Health-related Quality of Life (QoL) is a multidimensional construct that allows us to know the patient's perception of well-being, and how this perception is related to their illness and treatment.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Quality of Life, Radiotherapy; Complications
- Trial name
- NCT03720158
- Testing
- Omega 3 Group
- Where
- Mexico
- Volunteers
- 9 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Lung Cancer, Metastatic Cancer
Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer
RATIONALE: Studying samples of pleural fluid in the laboratory from patients with lung cancer may help doctors identify early lung cancer cells. It may also help the study of lung cancer in the future.
- Trial name
- NCT00897143
- Testing
- microarray analysis, mutation analysis, flow cytometry
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Hepatocellular Carcinoma, Adjuvant Therapy
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
This study aims to evaluate the efficacy and safety of donafenib as adjuvant therapy for postoperative patients with high-risk recurrent Hepatocellular Carcinoma. This is a multicenter, randomized controlled study.
- Trial name
- NCT06581315
- Testing
- Donafenib
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non-small Cell Lung Cancer
Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21
Erlotinib with concurrent radiotherapy has superior efficacy and comparable safety profile in unresectable stage III non-small cell lung cancer (NSCLC) patients with activating mutation of epidermal growth factor receptor (EGFR)…
- Trial name
- RECEL (NCT01714908)
- Testing
- Erlotinib w Concurrent Radiotherapy, etoposide/cis-platin (EP) w Concurrent Radiotherapy
- Where
- 19 sites in China
- Volunteers
- 100 people
- Sponsor
- Jinming Yu
Non-small Cell Lung Cancer
A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
This is a randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial to evaluate the efficacy and safety of Fruquintinib plus best supportive care in patients with advanced non-squamous non-small cell lung…
- Trial name
- NCT02590965
- Testing
- Fruquintinib
- Where
- 12 sites in China
- Volunteers
- 91 people
- Sponsor
- Hutchison Medipharma Limited
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer
This randomized phase III trial studies the side effects and how well intensity-modulated proton beam therapy works and compares it to intensity-modulated photon therapy in treating patients with stage III-IVB oropharyngeal…
- Conditions
- Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Trial name
- NCT01893307
- Testing
- Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Photon Beam Radiation Therapy
- Where
- 22 sites in United States
- Volunteers
- 440 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Basal Cell
Debulking Effect of Curretage on Basal Cell Carcinomas - a Histological Assessment.
The aim of this study was to compare histologically observed tumour infitration of basal cell carcinoma (bcc) lesions before and after curretage.A significant reduction of tumour depth would enable further bcc's included for…
- Trial name
- NCT00237107
- Testing
- Curretage
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Urothelial Carcinoma
Vasculogenic Mimicry in Urothelial Carcinoma
In this study, the investigators aim at: 1. Evaluate the presence of vasculogenic mimicry in urothelial carcinomas by CD31-PAS double staining. 2.
- Trial name
- NCT04295967
- Testing
- formalin fixed paraffin embedded blocks
- Volunteers
- 70 people
- Sponsor
- Assiut University
Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
This phase II trial studies how well giving pazopanib hydrochloride and anastrozole before surgery works in treating patients with stage II-III estrogen receptor-positive breast cancer.
- Conditions
- Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01394211
- Testing
- anastrozole, pazopanib hydrochloride, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Arizona
Stage IV Non-small Cell Lung Cancer
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
To define Phase 1/2 Maximum Tolerated Dose Study of Belinostat (PXD-101) in Combination with Paclitaxel plus Carboplatin in Chemotherapy-Naive Patients with Stage IV Non-Small-Cell Lung Cancer (NSCLC).
- Trial name
- NCT01310244
- Testing
- Belinostat, Carboplatin, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Acrotech Biopharma Inc.
Advanced Renal Cell Carcinoma
A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
The purpose of this study is to collect data to describe the safety and effectiveness of cabozantinib and nivolumab in combination as a first-line treatment in adults with aRCC with clear cell-component, according to real-world…
- Trial name
- CaboCombo (NCT05361434)
- Where
- 66 sites in Belgium, France and 6 more
- Volunteers
- 311 people
- Sponsor
- Ipsen
Hepatocellular Carcinoma
Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma
This is a non-randomized, prospective, pilot, Multicenter Study of Drug-eluting bead transarterial chemoembolization (DEB-TACE) using Doxorubicin-Loaded Embozene® Tandem™ Microspheres to treat hepatocellular carcinoma (HCC).
- Trial name
- MIRACLE I (NCT01798134)
- Testing
- TANDEM™
- Where
- 7 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Boston Scientific Corporation
Medullary Thyroid Carcinoma, Small Cell Lung Cancer ( SCLC )
68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis
Evaluate the safety of the novel radioactive nuclide-labeled cholecystokinin receptor (CCK2R) targeted molecular probe, 68Ga-YQ-CC05, in clinical application, and verify its effectiveness in tumor diagnosis.
- Conditions
- Medullary Thyroid Carcinoma, Small Cell Lung Cancer ( SCLC ), Gastric Adenocarcinoma
- Trial name
- NCT07914764
- Testing
- Intravenous injection of 68Ga-YQ-CC05 for PET-CT examination
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.